Jaguar Health Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

JAGX$0.44+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets


· · March 31, · · December 31,
(In thousands, except share and per share data) · 2024 · 2023
· · (unaudited) · · ·
Assets · · · · ·
Current assets:
Cash	$11,671	$6,469
Accounts receivable, net	1,512	1,967
Other receivable	202	217
Inventory	9,020	9,189
Prepaid expenses and other current assets	11,309	10,121
Total current assets	33,714	27,963
Property and equipment, net	484	496
Operating lease - right-of-use asset	1,289	1,176
Intangible assets, net	19,627	20,116
Other assets	275	1,012
Total assets	$55,389	$50,763

Liabilities, Redeemable Preferred stock and Stockholders' equity
Current liabilities:
Accounts payable	$3,320	$4,974
Accrued liabilities	3,461	3,798
Deferred revenue	170	—
Operating lease liability, current	469	348
Notes payable, net of discount (includes note designated at Fair Value Option amounting to $10.2 million as of March 31, 2024 and $0 December 31, 2023, respectively)	10,394	4,867
Total current liabilities	17,814	13,987
Operating lease liability, net of current portion	873	886
Deferred revenue - long term	680	—
Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $21.7 million as of March 31, 2024 and $31.0 million December 31, 2023, respectively)	21,719	30,993
Total liabilities	41,086	45,866

Commitments and contingencies (See Note 6)
Redeemable preferred stock: $0.0001 par value; 179 and 0 shares designated from 10,000.000 preferred stock authorized at March 31, 2024 and December 31, 2023; 99 and 0 shares issued and outstanding at March 31, 2024 and December 31, 2023	2,485	—

Stockholders' equity
Series G convertible preferred stock: $0.0001 par value; 137 and 137 shares designated from 10,000,000 preferred stock authorized at March 31, 2024 and December 31, 2023; 0 and 122 shares issued and outstanding at March 31, 2024 and December 31, 2023	—	—
Series H convertible preferred stock: $0.0001 par value; 105 and 105 shares designated from 10,000,000 preferred stock authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023	—	—
Series I convertible preferred stock: $0.0001 par value; 118 and 118 shares designated from 10,000,000 preferred stock authorized at March 31, 2024 and December 31, 2023; 0 and 56 shares issued and outstanding at March 31, 2024 and December 31, 2023	—	—
Common stock - voting: $0.0001 par value, 298,000,000 shares authorized at March 31, 2024 and December 31, 2023; 273,479,471 and 73,413,248 issued and outstanding at March 31, 2024 and December 31, 2023	27	7
Common stock - non-voting: $0.0001 par value, 50,000,000 shares authorized at March 31, 2024 and December 31, 2023; 9 shares issued and outstanding at March 31, 2024 and December 31, 2023	—	—
Additional paid-in capital	329,647	313,854
Noncontrolling interest	(180)	(64)
Accumulated deficit	(317,215)	(308,248)
Accumulated other comprehensive loss	(461)	(652)
Total stockholders' equity	11,818	4,897
Total liabilities, redeemable preferred stock and stockholders' equity	$55,389	$50,763

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.